Next, we tested the cytotoxic activity of DMF on CLL cells obtained from 5 additional patients who were under treatment with BTK inhibitors at the time of blood sampling (see Supplementary Table 2 for the clinico-biological characteristics and ongoing treatments): we observed a dose-dependent therapeutic effect even in this population (Fig. 2I). Here, BTK is linked to B-cell chronic lymphocytic leukemia.